Express Report
Nomination for Advocacy Council
NGO Connect Program

Intellectual Property News

AG IP News
  • Talal Abu-Ghazaleh Organization and Jordan Media City Sign Cooperation Agreement
    Special to ag-IP-news Agency AMMAN - Talal Abu-Ghazaleh Organization (TAG-Org) signed a cooperation agreement with Jordan Media City (JMC) to provide professional services in various fields. The MoU was signed at TAG-Org headquarters by TAG-Org Chairman HE Dr. Talal Abu-Ghazaleh and CEO of the Media City Mr. Radi AlKhas in the presence of representatives for both parties. Dr. Abu-Ghazaleh welcomed AlKhas by stressing the importance of media and its role as the Fourth Authority dealing with technical advancements to serve its mission and emphasizing TAG-Org’s willingness to offer its support and assistance to the Media City  in various fields of its expertise. Dr. Abu-Ghazaleh stated that TAG-Org is upgrading its own Internet Line shifting to a speed of 1.5 gigabyte instead of 450 megabyte which will enable the Organization to expand in the Arab world as the self-provider of Internet to all knowledge stations and offices in Arab countries, in addition to providing this service to research centers, Arab organizations and educational institutions.   AlKhas noted that fields of cooperation between the City and the Organization are numerous and will be fruitful, highlighting the great success achieved by TAG-Org at  Arab and global levels. He referred particularly to cooperation in the field of visual archive restoration and digital transformation which will offer digital documentation and serve various media institutions locally and regionally. According to the MoU, the two parties will form a joint team to study the potential for the provision of a number of services that include Provision of Internet TV and radio broadcasting services for smartphones and tablets, due to the expertise of TAG-Org in "iCloud" storage and that of JMC in TV broadcasting services through various platforms, cooperation in establishing a digital media center at a regional level, as well as cooperation in the field of visual archive restoration and digital transformation. The MoU also included fields of cooperation in Electronic archiving of media materials, sustaining a closer relationship between TAG-Org and JMC in developing future projects, establishing specialized digital stations at JMC and installing a solar photovoltaic system to cut energy costs.  
  • ICANN Publishes NomCom2 Review Survey for Community Input
    LOS ANGELES – The Analysis Group, the independent examiner conducting the second review of the ICANN Nominating Committee (NomCom2), announced a survey to collect input from those who have interacted with NomCom and/or have ideas for ways to improve it. Please share your input by taking the survey found at this link: The NomCom plays a critical role within ICANN. It nominates appointees to the ICANN Board, the Public Technical Identifiers (PTI) Board, the Generic Names Supporting Organization (GNSO) and Country Code Names Supporting Organization (ccNSO) Councils, and the At-Large Advisory Committee. Organizational reviews are mandated by ICANN Bylaws Section 4. This organizational review will assess how effectively the NomCom is operating, how well it is achieving its purpose, and if it is accountable to the multistakeholder community. Next Steps Following the survey, the independent examiner will attend ICANN60 to conduct further review work. The draft final report of the independent examiner will be posted for public comment, and the review is expected to conclude by mid-2018. NomCom Resources • NomCom Review wiki page: • NomCom homepage: ICANN's mission is to help ensure a stable, secure and unified global Internet. To reach another person on the Internet, you need to type an address – a name or a number – into your computer or other device. That address must be unique so computers know where to find each other. ICANN helps coordinate and support these unique identifiers across the world. ICANN was formed in 1998 as a not-for-profit public-benefit corporation with a community of participants from all over the world.  
  • Aclaris Therapeutics Issued US Patents Covering JAK Inhibitors for Treating Hair Loss Disorders
    MALVERN, Pa. - Aclaris Therapeutics Inc. announced in a press release that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 9,737,469 and US Patent No. 9,730,877, which are directed to methods related to the use and administration of certain janus kinase (JAK) inhibitors for treating hair loss disorders.  US Patent No. 9,730,877 covers the use of various JAK inhibitors, including tofacitinib, baricitinib, ruxolitinib and decernotinib, to treat androgenetic alopecia, also known as male/female pattern hair loss. Experienced by 70% of men and 40% of women at some point in their lives, androgenetic alopecia is a genetic disorder and the most common cause of hair loss. The ‘877 Patent contains 22 claims and expires in November 2031. US Patent No. 9,737,469 covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.  Additional issued claims pertain to methods of using baricitinib to treat particular phenotypes of alopecia areata, as well as to treat other hair loss disorders. The ‘469 Patent contains 10 claims and expires in November 2031.  These newly allowed patents are owned by The Trustees of Columbia University in the City of New York and exclusively licensed to Aclaris, and are the latest US patents to issue in connection with Aclaris' JAK drug development program for hair loss disorders. “We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia.  These new issuances continue to expand the breadth and depth of our JAK inhibitor intellectual property portfolio covering methods of use for certain JAK inhibitors for the treatment of hair loss disorders. The issuance of these patents is another successful step in the development of a robust patent portfolio relating to JAK inhibition and hair loss,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. Aclaris has exclusively licensed several patents and patent applications involving novel selective JAK 1/3 inhibitors, including a patent portfolio from Rigel Pharmaceuticals, Inc. that covers Aclaris’ product candidates ATI-50001 and ATI-50002, which are oral and topical formulations, respectively, also being developed as potential treatments for alopecia areata.  Additionally, Aclaris has exclusively licensed a patent portfolio from Columbia University directed to methods of using JAK inhibitors for the treatment of alopecia areata, androgenetic alopecia, and other dermatological conditions.  This portfolio includes the recently issued U.S. patents discussed above, as well as an issued U.S. patent directed to methods of treating alopecia areata, androgenetic alopecia and other hair loss disorders by administering ruxolitinib and issued patent claims in Japandirected to pharmaceutical compositions comprising ruxolitinib, baricitinib or other JAK inhibitors for use in treating alopecia areata, androgenetic alopecia and other hair loss disorders.  

My Caring Brands

Brands and Fakes has aligned the capabilities of the service delivery eco system with the industry verticals, so that the Brands under various industry verticals and sub verticals are able to get services from expertise in their specific domains.